{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"TuHURA Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"HURA"},"Address":{"label":"Address","value":"12707 HIGH BLUFF DRIVE,SUITE 200 SUITE 150, SAN DIEGO, California, 92130, United States"},"Phone":{"label":"Phone","value":"+1 858 350-4364"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications."},"CompanyUrl":{"label":"Company Url","value":"https://www.kintara.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}